Clinical Trial Update: Assessing an Oral EGFR Inhibitor, Sunvozertinib in Patients Who Have Advanced Non-small Cell Lung Cancer With EGFR or HER2 Mutation (WU-KONG1) [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial update on sunvozertinib, an oral EGFR inhibitor, in adults with advanced non-small cell lung cancer harboring EGFR or HER2 mutations,…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Sunvozertinib (Sunvozertinib)

Snippet

Sponsor: Dizal Pharmaceuticals | Conditions: Non-Small Cell Lung Cancer | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2025-12-03